a pipeline focused on delivery of parkin therapeutics to patients
Our ultimate goal is to translate the positive clinical outcome from our initial genetic population to all Parkinson’s Disease patients. Beyond that, because of the science of Parkin, we can apply our therapeutic to many disease indications.
Parkin works to repair the mitochondrial machinery that generates energy for all of the cells in our bodies. This widely understood and accepted fact lays the groundwork for the application of our therapy across many indications where cellular stress and the ability to continue to produce energy are nearly depleted.
Our discovery programs are focused on these important disease areas in which patients are suffering with enormous unmet medical needs.
We are confident that our strategy to identify appropriate patient populations, define clear clinical endpoints, and deliver high-quality gene therapy products will result in positive clinical outcomes.
